BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares. Sentiment for ...

In the preceding three months, 10 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the ...

Genetic testing, also known as DNA testing, involves obtaining DNA from a sample of cells in your body to identify specific genes, chromosomes, or proteins, including those that are faulty (known as ...

A genetic data giant is falling, and it’s unclear what will happen to millions of people’s most intimate personal information in the aftermath. On March 23, DNA testing company 23andMe ...

Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million during the quarter, compared to analyst estimates of $210. ...

Genetic testing company 23andMe filed for bankruptcy in the United States on Sunday, raising concerns about the fate of highly sensitive genetic data from its 15 million customers. The company, best ...

Data from online genetics services have also been used by law enforcement to help solve crimes, although 23andMe’s current policy says it won’t share information with police without a legally ...